Press release
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
− R&D Organization Positioned to Deliver Next Wave of Transformative RNAi Therapeutics – − Goal of Delivering RNAi Therapeutics to All Major Tissues by 2030
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"\n− R&D Organization Positioned to Deliver Next Wave of Transformative RNAi Therapeutics –\n\n\n− Goal of Delivering RNAi Therapeutics to All Major Tissues by 2030 –\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed Executive Vice President, Chief Research and Development Officer to oversee an integrated R&D organization. Building on the launch of AMVUTTRA® in transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Alnylam is entering a new phase of growth, and a combined R&D organization will accelerate pipeline progress by fostering earlier collaboration, faster decision-making, and more agile responses to both scientific opportunity and patient need.\n\n\n“I could not be more excited for Pushkal to take the helm of the combined R&D organization, given his strategic vision, operational excellence and impressive track record building and steering an industry-leading, innovative drug development organization that has delivered a new class of medicines to the world,” said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. “In recent years, we’ve made remarkable progress across all facets of our innovation engine, achieving numerous drug approvals and positive Phase 3 readouts, and rapidly increasing the size of our clinical pipeline. As our science has advanced, so has the need for tighter alignment across Research and Development to ensure that we continue to scale our impact and transform the lives of patients across a growing number of diseases.”\n\n\n“As we begin this exciting new chapter, I am energized about what lies ahead for Alnylam R&D and for patients,” said Dr. Garg. “I believe we are just beginning to scratch the surface of what RNAi therapeutics can do to improve human health. Our ambition is to deliver RNAi therapeutics to every major tissue in the body and thereby address many additional diseases that lack effective treatments. It’s a privilege for me to have the opportunity to work with and lead an integrated R&D organization that has already validated a new class of medicines so that we can imagine the next generation of treatments, drive them from the lab to approval, and help patients live healthier lives.”\n\n\nDr. Garg joined Alnylam in 2014 ...